| Record 5363 View: Standard | Glossary HistCite Guide |
|
Author(s): Liu R; Barkhordarian H; Emadi S; Park CB; Sierks MR
Title: Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42
Source: NEUROBIOLOGY OF DISEASE 20 (1): 74-81
Date: 2005 OCT
Document Type: Journal : Article
DOI:
Language: English
Comment:
Address: Arizona State Univ, Dept Chem & Mat Engn, Tempe, AZ 85287 USA.
Reprint: Sierks, MR, Arizona State Univ, Dept Chem & Mat Engn, Box 876006,
Tempe, AZ 85287 USA. E-mail: sierks@asu.edu
Author Keywords: Alzheimer's disease; beta-amyloid; trehalose; aggregation; atomic force
microscope; cytotoxicity; oligomers
KeyWords Plus: AMYLOID-BETA-PEPTIDE; ATOMIC-FORCE MICROSCOPY; ANTIBODY LIGHT-CHAINS;
ALZHEIMERS-DISEASE; IN-VITRO; A-BETA; MOUSE MODEL; FIBRIL FORMATION;
PROTEIN; FIBRILLOGENESIS
Abstract: A key event in Alzheimer's disease (AD) pathogenesis is the conversion of the peptide beta-amyloid (A beta) from its soluble monomeric form into various aggregated morphologies in the brain. Preventing aggregation of A beta is being actively pursued as a primary therapeutic strategy for treating AD. Trehalose, a simple disaccharide, has been shown to be effective in preventing the deactivation of numerous proteins and in protecting cells against stress. Here, we show that trehalose is also effective in inhibiting aggregation of A beta and reducing its cytotoxicity, although it shows differential effects toward A beta 40 and A beta 42. When co-incubated with A 40, trehalose inhibits formation of both fibrillar and oligomeric morphologies as determined by fluorescence staining and atomic force microscopy (AFM). However, when co-incubated with A beta 42, trehalose inhibits formation only of the fibrillar morphology, with significant oligomeric formation still present. When aggregated mixtures were incubated with SH-SY5Y cells, trehalose was shown to reduce the toxicity of A beta 40 mixtures, but not A beta 42. These results provide additional evidence that aggregation of A beta into soluble oligomeric forms is a pathological step in AD and that A beta 42 In particular is more susceptible to forming these toxic oligomers than A beta 40. These results also suggest that the use of trehalose, a highly soluble, low-priced sugar, as part of a potential therapeutic cocktail to control A peptide aggregation and toxicity warrants further study. (c) 2005 Elsevier Inc. All rights reserved.
Cited References: ALLISON SD, 1999, ARCH BIOCHEM BIOPHYS, V365, P289 ARGUELLES JC, 2000, ARCH MICROBIOL, V174, P217 ARORA A, 2004, FEBS LETT, V564, P121 ASHURFABIAN O, 2003, PEPTIDES, V24, P1413 BANG OY, 2004, NEUROBIOL DIS, V16, P21 BELTON PS, 1994, BIOPOLYMERS, V34, P957 BENAROUDJ N, 2001, J BIOL CHEM, V276, P24261 BERGAMASCHINI L, 2004, J NEUROSCI, V24, P4181 BESSELING NAM, 1997, J PHYS CHEM B, V101, P7604 CARNINCI P, 1998, P NATL ACAD SCI USA, V95, P520 CROWE JH, 1998, ANNU REV PHYSIOL, V60, P73 DALFONSO L, 2003, EUR J BIOCHEM, V270, P2497 FARRIS W, 2003, P NATL ACAD SCI USA, V100, P4162 FEOFILOVA EP, 2003, PRIKL BIOKHIM MIKRO, V39, P5 FINDEIS MA, 1999, BIOCHEMISTRY-US, V38, P6791 FINDEIS MA, 2000, BBA-MOL BASIS DIS, V1502, P76 GOATE A, 1991, NATURE, V349, P704 HAGEN SJ, 1995, SCIENCE, V269, P959 HARPER JD, 1999, BIOCHEMISTRY-US, V38, P8972 HU JG, 2001, J BIOL CHEM, V276, P47863 KAUSHIK JK, 2003, J BIOL CHEM, V278, P26458 KAYED R, 2003, SCIENCE, V300, P486 KIRKITADZE MD, 2002, J NEUROSCI RES, V69, P567 LASHUEL HA, 2002, NATURE, V418, P291 LEVINE H, 1993, PROTEIN SCI, V2, P404 LEVINE H, 2002, CURR MED CHEM, V9, P1121 LI J, 2004, FASEB J, V18, P962 LINS RD, 2004, PROTEINS, V55, P177 LIU R, 2004, BIOCHEMISTRY-US, V43, P9999 LIU RT, 2004, BIOCHEMISTRY-US, V43, P6959 LUO Y, 2002, P NATL ACAD SCI USA, V99, P12197 MACLEAN DS, 2002, J PHARM SCI, V91, P2220 MANOUTCHARIAN K, 2004, NEUROBIOL DIS, V17, P114 NICHOLS MR, 2002, BIOCHEMISTRY-US, V41, P6115 NORDBERG A, 2002, J NEUROCHEM, V81, P655 ONO K, 2004, J NEUROSCI RES, V75, P742 PAIVA CLA, 1996, BIOTECHNOL ANN REV, V2, P293 PETRUCELLI L, 2004, HUM MOL GENET, V13, P703 PODLISNY MB, 1998, BIOCHEMISTRY-US, V37, P3602 RANGAN SK, 2003, BIOCHEMISTRY-US, V42, P14328 SCHENK D, 1999, NATURE, V400, P173 SELKOE DJ, 1997, SCIENCE, V275, P630 SHEARMAN MS, 1995, J NEUROCHEM, V65, P218 SHIMIZU T, 2002, J NEUROSCI RES, V70, P451 SHLYAKHTENKO LS, 2000, NUCLEIC ACIDS RES, V28, P3472 SHLYAKHTENKO LS, 2003, ULTRAMICROSCOPY, V97, P263 SIMOLA M, 2000, MOL MICROBIOL, V37, P42 SINGER MA, 1998, MOL CELL, V1, P639 SINGER MA, 1998, TRENDS BIOTECHNOL, V16, P460 SOLAPENNA M, 1997, EUR J BIOCHEM, V248, P24 SOTO C, 1998, NAT MED, V4, P822 STINE WB, 2003, J BIOL CHEM, V278, P11612 TANAKA M, 2004, NAT MED, V10, P148 WALSH DM, 1999, J BIOL CHEM, V274, P25945 XIE J, 2004, NEUROBIOL DIS, V16, P150 |